Saturday, July 11, 2026
🇺🇸 FDA

Drug profile · INN

humalog

humalog is a insulin receptor agonist.

NMPA: clinical trials
Patents linked 0
Pipeline programs 3
News articles 0
Drug details — humalog
Class
—
Route
—
Patents
0
Programs
3
Data quality
0.70
← All drugs Search patents Pipeline programs Drug news hub Event calendar

Quick answer

humalog is a insulin receptor agonist.

Key facts

INN humalog
Mechanism Insulin receptor agonist
Target Insulin receptor

Mechanism of action

Insulin receptor agonist

Primary target: Insulin receptor

Approval history

Authority Status Date
NMPA clinical trials —

Pipeline programs

Browse pipeline
  1. Humalog Phase 2 · HALOZYME THERAPEUTICS · Diabetes Mellitus, Type 2
  2. Humalog Phase 2 · HALOZYME THERAPEUTICS · Type 1 Diabetes Mellitus
  3. Humalog Phase 1 · HALOZYME THERAPEUTICS · Diabetes Mellitus

Related & competitor drugs

Browse all drugs
  1. insulin aspart Alimentary tract and metabolism (A10)
  2. insulin aspart protamine recombinant Insulin receptor agonist
  3. insulin aspart recombinant Insulin receptor agonist
  4. insulin degludec Alimentary tract and metabolism (A10)
  5. insulin detemir Alimentary tract and metabolism (A10)
  6. insulin detemir recombinant Insulin receptor agonist

Frequently asked questions

What is humalog?

humalog is a insulin receptor agonist.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.